dc.contributor.authors |
Akpinar, Seval; Dogu, Mehmet Hilmi; Celik, Serhat; Ekinci, Omer; Hindilerden, Ipek Yonal; Dal, Mehmet Sinan; Davulcu, Eren Arslan; Tekinalp, Atakan; Hindilerden, Fehmi; Ozcan, Busra Gokce; Hacibekiroglu, Tuba; Erkurt, Mehmet Ali; Bagci, Metin; Namdaroglu, Sinem; Korkmaz, Gulten; Bilgir, Oktay; Cagliyan, Gulsum Akgun; Ozturk, Hacer Berna Afacan; Serin, Istemi; Tiryaki, Tarik Onur; Ozatli, Duzgun; Korkmaz, Serdal; Ulas, Turgay; Eser, Bulent; Turgut, Burhan; Altuntas, Fevzi |
|
dc.date.accessioned |
2022-12-20T13:25:40Z |
|
dc.date.available |
2022-12-20T13:25:40Z |
|
dc.date.issued |
2022 |
|
dc.identifier.issn |
2152-2650 |
|
dc.identifier.uri |
http://dx.doi.org/10.1016/j.clml.2021.09.010 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/99407 |
|
dc.description |
Bu yayının lisans anlaşması koşulları tam metin açık erişimine izin vermemektedir. |
|
dc.description.abstract |
We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/Methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the par ticipating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+ /p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were >= grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atr ial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare dur ing the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. (C) 2021 Elsevier Inc. All rights reserved. |
|
dc.language |
English |
|
dc.language.iso |
eng |
|
dc.relation.isversionof |
10.1016/j.clml.2021.09.010 |
|
dc.subject |
Oncology |
|
dc.subject |
Hematology |
|
dc.subject |
Chronic lymphocytic leukemia |
|
dc.subject |
Bruton tyrosine kinase |
|
dc.subject |
Ibrutinib |
|
dc.subject |
Relapsed/refractory |
|
dc.subject |
p53 mutation |
|
dc.title |
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL |
|
dc.contributor.authorID |
Dogu, Mehmet Hilmi/0000-0001-7237-2637 |
|
dc.contributor.authorID |
Celik, Serhat/0000-0002-1052-9800 |
|
dc.contributor.authorID |
tiryaki, tarik onur/0000-0002-0096-5684 |
|
dc.contributor.authorID |
AKPINAR, SEVAL/0000-0002-6961-8971 |
|
dc.identifier.volume |
22 |
|
dc.identifier.startpage |
169 |
|
dc.identifier.endpage |
173 |
|
dc.relation.journal |
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA |
|
dc.identifier.issue |
3 |
|
dc.identifier.doi |
10.1016/j.clml.2021.09.010 |
|
dc.identifier.eissn |
2152-2669 |
|
dc.contributor.author |
Akpinar, Seval |
|
dc.contributor.author |
Dogu, Mehmet Hilmi |
|
dc.contributor.author |
Celik, Serhat |
|
dc.contributor.author |
Ekinci, Omer |
|
dc.contributor.author |
Hindilerden, Ipek Yonal |
|
dc.contributor.author |
Dal, Mehmet Sinan |
|
dc.contributor.author |
Davulcu, Eren Arslan |
|
dc.contributor.author |
Tekinalp, Atakan |
|
dc.contributor.author |
Hindilerden, Fehmi |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
|